Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Stomach interference in 82Rb-PET myocardial perfusion imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Early risk stratification using Rubidium-82 positron emission tomography in STEMI patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Rubidium-82 PET imaging is feasible in a rat myocardial infarction model

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Diabetes i familien – familien og diabetes

    Publikation: Bidrag til tidsskriftBidrag til avis - Kommentar/debatFormidling

  2. Diabetespatienter er afhængige af et løft af det nære sundhedsvæsen

    Publikation: AndetUdgivelser på nettet - Net-publikationFormidling

  3. Forord

    Publikation: Bidrag til bog/antologi/rapportBidrag til bog/antologiFormidling

Vis graf over relationer

BACKGROUND: The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR).

METHODS AND RESULTS: CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by (18)F-FDG and (15)O-H2O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide.

CONCLUSION: Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR.

TRIAL REGISTRATION: Trial registry: http://www.ClinicalTrials.org . Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1.

OriginalsprogEngelsk
TidsskriftJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Vol/bind26
Udgave nummer2
Sider (fra-til)585-597
ISSN1071-3581
DOI
StatusUdgivet - 2018

ID: 51495803